CN1729015A - 保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素 - Google Patents

保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素 Download PDF

Info

Publication number
CN1729015A
CN1729015A CNA038249154A CN03824915A CN1729015A CN 1729015 A CN1729015 A CN 1729015A CN A038249154 A CNA038249154 A CN A038249154A CN 03824915 A CN03824915 A CN 03824915A CN 1729015 A CN1729015 A CN 1729015A
Authority
CN
China
Prior art keywords
epo
erythropoietin
oligonucleotide chain
chain
life
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038249154A
Other languages
English (en)
Chinese (zh)
Inventor
A·切拉米
J·斯马特
M·布赖恩斯
C·切拉米
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kenneth s warren research institute
Warren Pharmaceuticals Inc
Original Assignee
Kenneth s warren research institute
Warren Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth s warren research institute, Warren Pharmaceuticals Inc filed Critical Kenneth s warren research institute
Publication of CN1729015A publication Critical patent/CN1729015A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Analytical Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
CNA038249154A 2002-09-09 2003-09-09 保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素 Pending CN1729015A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40902002P 2002-09-09 2002-09-09
US60/409,020 2002-09-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2008101490873A Division CN101371920A (zh) 2002-09-09 2003-09-09 保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素

Publications (1)

Publication Number Publication Date
CN1729015A true CN1729015A (zh) 2006-02-01

Family

ID=31978712

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2008101490873A Pending CN101371920A (zh) 2002-09-09 2003-09-09 保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素
CNA038249154A Pending CN1729015A (zh) 2002-09-09 2003-09-09 保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNA2008101490873A Pending CN101371920A (zh) 2002-09-09 2003-09-09 保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素

Country Status (15)

Country Link
EP (1) EP1545586A4 (pt)
JP (1) JP2006511468A (pt)
KR (1) KR20050083682A (pt)
CN (2) CN101371920A (pt)
AU (1) AU2003273297A1 (pt)
BR (1) BR0314152A (pt)
CA (1) CA2497960A1 (pt)
EA (1) EA007812B1 (pt)
IL (1) IL174178A0 (pt)
IS (1) IS7731A (pt)
MX (1) MXPA05002617A (pt)
NO (1) NO20051714L (pt)
PL (1) PL375741A1 (pt)
WO (1) WO2004022577A2 (pt)
ZA (1) ZA200505423B (pt)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102746405A (zh) * 2012-07-24 2012-10-24 深圳赛保尔生物药业有限公司 重组人促红素的连续聚乙二醇化反应方法
CN101671388B (zh) * 2008-09-09 2013-01-02 曹国栋 血脑屏障穿透性促红细胞生成素及其应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
WO2006061853A2 (en) * 2004-12-10 2006-06-15 Serum Institute Of India Limited Novel erythropoietic compounds and a process for producing erythropoietic compounds
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
DK2594279T3 (en) 2005-08-05 2018-01-08 Araim Pharmaceuticals Inc Tissue-protecting peptides and uses thereof
CN111346213A (zh) 2008-01-22 2020-06-30 阿拉伊姆药品公司 用于预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物
RU2475273C1 (ru) * 2012-04-02 2013-02-20 Юлия Николаевна Козлова Способ получения полимерного цемента медицинского назначения
RU2664588C2 (ru) * 2015-11-05 2018-08-21 Закрытое Акционерное Общество "Биокад" Пролонгированный фактор эритропоэза человека и лекарственное средство на его основе
JP2019523633A (ja) 2016-04-29 2019-08-29 アライム ファーマシューティカルズ，インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド
CN112741895A (zh) * 2021-01-19 2021-05-04 中国人民解放军陆军军医大学 Epo类似物在制备治疗脓毒症药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
JP5022551B2 (ja) * 2000-04-21 2012-09-12 アムジエン・インコーポレーテツド 貧血の予防及び治療用の方法及び組成物
HU230874B1 (hu) * 2000-05-15 2018-11-29 F. Hoffmann-La Roche Ag Pegilezett humán eritropoietin-fehérjét tartalmazó, szobahőmérsékleten stabil folyékony gyógyászati készítmények

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101671388B (zh) * 2008-09-09 2013-01-02 曹国栋 血脑屏障穿透性促红细胞生成素及其应用
CN102746405A (zh) * 2012-07-24 2012-10-24 深圳赛保尔生物药业有限公司 重组人促红素的连续聚乙二醇化反应方法

Also Published As

Publication number Publication date
AU2003273297A1 (en) 2004-03-29
CA2497960A1 (en) 2004-03-18
IS7731A (is) 2005-03-08
KR20050083682A (ko) 2005-08-26
WO2004022577A3 (en) 2004-09-16
EP1545586A2 (en) 2005-06-29
WO2004022577A2 (en) 2004-03-18
BR0314152A (pt) 2005-07-12
JP2006511468A (ja) 2006-04-06
IL174178A0 (en) 2006-08-01
EP1545586A4 (en) 2007-09-26
PL375741A1 (en) 2005-12-12
NO20051714L (no) 2005-06-06
CN101371920A (zh) 2009-02-25
AU2003273297A8 (en) 2004-03-29
ZA200505423B (en) 2008-08-27
MXPA05002617A (es) 2005-09-08
EA007812B1 (ru) 2007-02-27
EA200500473A1 (ru) 2005-10-27

Similar Documents

Publication Publication Date Title
CN1882355A (zh) 保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素
JP6549741B2 (ja) ペグ化ｏｘｍ変異体
JP6491621B2 (ja) 組織保護ペプチド及びその使用
KR100985615B1 (ko) 에리트로포이에틴-응답 세포, 조직 및 기관의 보호, 회복 및 향상
US20050176627A1 (en) Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
EA010099B1 (ru) Пептиды, которые связываются с рецептором к эритропоэтину, и способы их применения
EA010200B1 (ru) Рекомбинантные тканезащитные цитокины и кодирующие их нуклеиновые кислоты для защиты, восстановления и усиления чувствительных клеток, тканей и органов
CN107108711A (zh) 包含肽变异体的药物组合物及其使用方法
CN104023739A (zh) 长效glp-1/胰高血糖素受体激动剂
EA014528B1 (ru) Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина и их применение
CN1729015A (zh) 保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素
TW201838647A (zh) 對胰島素受體有降低親和性之胰島素類似物之接合物及其用途
JP2018517697A (ja) ペグ化オキシントモジュリン変異体
US20190160152A1 (en) Long-acting oxyntomodulin formulation and methods of producing and administering same
AU2004260543A1 (en) Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
KR20060132803A (ko) 내인성 에리트로포이에틴의 조직 보호 활성을 유지하는장기 작용성 에리트로포이에틴

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1087641

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1087641

Country of ref document: HK